90% of paperwork submitted by Bharat Biotech, say sourcesThe government on Monday “took stock” of Bharat Biotech’s application process with the World Health Organisation (WHO) for regulatory clearances for the Covaxin vaccine, as an inter-ministerial group led by Foreign Secretary Harsh Shringla met with company representatives in Delhi. “On the issue of WHO’s authorisation for Emergency Use Listing (EUL), BBIL noted that they had submitted 90% of the documentation required for EUL to WHO. Bharat Biotech is yet to publish results in any peer-reviewed journal, of its Phase-3 trials and has so far only announced interim clinical results claiming 81% efficacy. Also read: India to push for Covaxin recognition by WHO and EUICMR and Bharat Biotech are partners in developing the vaccine as well as the clinical trials. Also read: India approves COVID-19 vaccines Covishield and Covaxin for emergency useAccording to the sources, government and BBIL representatives also discussed their forays into other markets, which include 11 countries that have granted Covaxin regulatory approval and “11 companies in 7 countries” that have expressed an interest in technology transfer and production of Covaxin.

Source: The Hindu May 24, 2021 17:17 UTC